Sensei Biotherapeutics, Inc. 8-K

What Happened

• On June 10, 2026 Sensei Biotherapeutics, Inc. held its 2026 annual meeting and filed an 8-K reporting that stockholders approved several corporate actions: the 2026 Equity Incentive Plan (the “2026 Plan”), the 2026 Employee Stock Purchase Plan (the “2026 ESPP”), and an amendment to increase authorized common shares from 12,500,000 to 300,000,000 (effective June 10, 2026).
• Stockholders also elected two directors (Bob Holmen and Kristian Humer) and ratified Deloitte & Touche LLP as the independent auditor. The meeting record date showed 1,341,140 shares outstanding, with 1,077,174 shares (80.32%) present or represented by proxy.

Key Details

• 2026 Plan initial share reserve: 2,671,981 shares plus up to 311,164 shares recycled from the 2021 Plan; annual automatic increases on Jan 1 (2027–2036) equal to 5% of outstanding common stock (or less as set by the Board).
• 2026 ESPP initial reserve: 267,198 shares; annual automatic increases on Jan 1 (2027–2036) equal to the lesser of 1% of outstanding common stock or two times the initial reserve (board can set a smaller increase).
• Amendment to certificate of incorporation increasing authorized common stock to 300,000,000 was filed with the Delaware Secretary of State and became effective June 10, 2026.
• Vote outcomes (selected): Director elections — Bob Holmen: 741,993 For / 23,529 Withheld; Kristian Humer: 741,275 For / 24,247 Withheld. 2026 Plan approved: 484,662 For / 266,010 Against (311,652 broker non-votes). 2026 ESPP approved: 487,784 For / 262,910 Against (311,652 broker non-votes). Proposal approving issuance on conversion of Series B preferred (potential >20% and change of control under Nasdaq rules) was also approved.

Why It Matters

• The approved equity plans give the company board flexibility to grant stock options, restricted stock units and purchase-plan shares for employee compensation and recruiting; the planned automatic annual increases provide a steady replenishment mechanism through 2036.
• Increasing authorized shares to 300M provides the company legal capacity to issue substantially more common stock for financings, equity awards or conversions (including the Series B preferred conversion approved by stockholders), which can dilute existing shareholders when shares are issued.
• Ratification of the auditor and election of directors maintain governance continuity; the vote tallies and presence of broker non-votes highlight that institutional voting and outstanding preferred conversions were material elements of this meeting.